Pathways to approval of pediatric cardiac devices in the United States: challenges and solutions

Robert H Beekman1, Brian W Duncan, Donald J Hagler

  • 1Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. rbeekman@cchmc.org

Pediatrics
|July 1, 2009
PubMed

Insights

Pediatric patients face unmet medical device needs. This review examines US Food and Drug Administration (FDA) processes and proposes alternate pathways for pediatric cardiac device approval.

Area of Science:

  • Pediatric cardiology and cardiac surgery
  • Medical device regulation

Background:

  • Children often have unique medical device needs not met by current options.
  • Existing regulatory pathways may not adequately address pediatric cardiac devices.

Purpose of the Study:

  • To review current US Food and Drug Administration (FDA) regulatory processes for medical devices.
  • To identify challenges in evaluating and approving cardiac devices for pediatric use.
  • To discuss alternative regulatory pathways for pediatric cardiac devices.

Main Methods:

  • Review of current US FDA regulatory guidelines.
  • Analysis of unique aspects of pediatric cardiology and cardiac surgery.
  • Discussion of potential alternative approval pathways.

Main Results:

  • Current regulatory processes present challenges for pediatric cardiac devices.
  • Specific aspects of pediatric cardiology and surgery complicate device evaluation.
  • Alternative pathways may be necessary to facilitate device approval for children.

Conclusions:

  • Children require specialized cardiac devices and technologies.
  • The current regulatory framework needs adaptation to meet the needs of pediatric patients.
  • Exploring alternate pathways is crucial for improving access to innovative cardiac devices for children.

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...